Literature DB >> 29148608

Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient.

Ilona Anna Baraniak1, Matthew B Reeves1, Paul D Griffiths1.   

Abstract

In this review article, we consider results suggesting that transmission of human cytomegalovirus (HCMV) from a donor of a solid organ to an immunologically naive individual can be reduced. Two randomized controlled trials have been conducted recently, one of active immunization of recipients pretransplant and another of passive immunization with monoclonal antibodies specific for HCMV given at the time of transplant. Although the available data are encouraging-providing evidence of a reduction in the incidence of HCMV viraemia-they fall short of what would be required to prove definitively that transmission has been completely prevented. Here, we reflect on these studies and propose a set of 5 criteria, which, if satisfied in the future, could be taken as proof that active and/or passive immunization against HCMV effectively interrupts transmission of virus from the donor. We suggest that these criteria are considered when designing future randomized controlled trials.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cytomegalovirus; gB/MF59 vaccine; interruption of CMV transmission

Mesh:

Substances:

Year:  2017        PMID: 29148608     DOI: 10.1002/rmv.1958

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  4 in total

1.  Choice of Study Populations for Vaccines.

Authors:  Paul Griffiths; Brenna Hughes
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

2.  Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.

Authors:  Ilona Baraniak; Florian Kern; Pavlo Holenya; Paul Griffiths; Matthew Reeves
Journal:  J Infect Dis       Date:  2019-06-19       Impact factor: 5.226

Review 3.  A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection.

Authors:  Don Jeffrey Diamond; Corinna La Rosa; Flavia Chiuppesi; Heidi Contreras; Sanjeet Dadwal; Felix Wussow; Supriya Bautista; Ryotaro Nakamura; John A Zaia
Journal:  Expert Rev Vaccines       Date:  2018-10-03       Impact factor: 5.217

4.  Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.

Authors:  Ilona Baraniak; Ariane C Gomes; Isabella Sodi; Toby Langstone; Emily Rothwell; Claire Atkinson; Sylvie Pichon; Fabienne Piras-Douce; Paul D Griffiths; Matthew B Reeves
Journal:  EBioMedicine       Date:  2019-11-15       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.